• Cullinan Therapeutics and Taiho Oncology announced Phase 2 REZILIENT2 results showing zipalertinib activity against brain metastases in patients with mutation-defined lung cancer.
• Patients had non-small cell lung cancer harboring EGFR exon 20 insertions or other uncommon EGFR mutations, with active central nervous system metastases.
• Zipalertinib produced durable intracranial responses and was well tolerated, supporting continued evaluation in this difficult-to-treat population.
• Results will be presented October 26, 2026, at the European Society for Medical Oncology Congress in Madrid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019022270) on October 19, 2026, and is solely responsible for the information contained therein.